References
- Ezard N, Lintzeris N, Odgers P, et al. An evaluation of community methadone services in Victoria. Australia: Results of a client survey. Drug Alcohol Rev 1999; 18: 417–423
- Lintzeris N, Ritter A, Panjari M, Clark N, Kutin J, Bammer G. Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial. Am J Addict/Am Acad Psychiatrists Alcohol Addict 2004; 13(Suppl 1)S29–S41
- Victorian Department of Health Services. The Victorian drug statistics handbook: patterns of drug use and related harm in Victoria. Victorian Department of Human Services, Melbourne 2004
- Muhleisen P, Panjari M, Lee N. Buprenorphine dispensing in a cohort of community pharmacies in Victoria. Australian Pharmacist. 2003; 22: 229–234
- Muhleisen P, Lintzeris N, Koutroulis G, et al. Evaluation of methadone dispensing in community pharmacies in Victoria. 1998
- Jenkinson R A, Clark N C, Fry C L, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?. Addiction 2005; 95: 197–205
- Herald-Sun. Heroin switch drug warning. Herald Sun, Melbourne, Victoria 1 December, 2002
- Jenkinson R, Fry C, Miller P. Victorian drug trends 2002: findings from the Illicit Drug Reporting System (IDRS). University of NSW, Sydney 2002, National Drug and Alcohol Research Centre Technical Report no.145
- Jenkinson R, O'Keeffe B. Victorian drug trends 2004: findings from the Illicit Drug Reporting System (IDRS). University of NSW, Sydney 2004; 1–81
- Aboltins C A, Allen P, Daffy J R. Fungal endophthalmitis in intravenous drug users injecting buprenorphine contaminated with oral Candida species. Med J Aust 2005; 182: 427
- Cassoux N, Bodaghi B, Lehoang P, Edel Y. Presumed ocular candidiasis in drug misusers after intravenous use of oral high dose buprenorphine (Subutex). Br J Ophthalmol 2002; 86: 940–941
- Loo H W, Yam A KT, Tan T C, Peng Y P, Teoh L C. Severe upper limb complications from parenteral abuse of Subutex. Ann Acad Med Sing 2005; 34: 575–578
- Reynaud M, Tracqui A, Petit G, Potard D, Courty P. Six deaths linked to misuse of buprenorphine – benzodiazepine combinations. Am J Psychiatry 1998; 155: 448–449
- Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001; 121: 65–69
- Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998; 22: 430–434
- Buprenorphine Diversion. Drugs and poisons unit newsletter, Sect. p1. May, 2003
- Mattick R P, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004, issue 3, CD002207
- Jasinski D R, Pevnick J S, Griffith J D. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35: 501–516
- Barnett P G, Rodgers J H, Bloch D A. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001; 96: 683–690
- Supervision of buprenorphine doses. Drugs and poisons unit newsletter, Sect. p4. Department of Human Services. November, 2002
- Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003; 69: 175–181
- Jenkinson R, O'Keeffe B. Victorian drug trends 2004: findings from the Illicit Drug Reporting System (IDRS). University of NSW, Sydney 2004, National Drug and Alcohol Research Centre Technical Report no.212
- Jenkinson R A, Clark N C, Fry C L, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?. Addiction 2005; 100: 197–205